Targeted Nanoparticles for Glaucoma Treatment via Schlemm's Canal
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current glaucoma treatments do not effectively address the increased outflow resistance in the conventional outflow pathway, leading to elevated intraocular pressure, and existing drug delivery methods cause off-target effects due to non-specific targeting of cell softening agents.
Innovation Solution
Development of a targeted delivery system using poly(ethylene glycol)-block-poly(propylene sulfide) (PEG-b-PPS) nanocarriers loaded with latrunculin A, equipped with a FLT4-binding peptide that specifically targets Schlemm's canal endothelial cells, reducing intraocular pressure while minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cell softening agents are administered to treat glaucoma, then intraocular pressure is reduced, but off-target effects and side effects occur due to non-specific targeting
Solution Approach 1:
The patent uses a nanocarrier system as an intermediary to deliver cell softening agents specifically to Schlemm's canal endothelial cells. The nanocarrier comprises a targeting moiety with a peptide that binds to FLT4 receptors on SC endothelial cells, a PEG spacer, and a hydrophobic anchor that integrates into the nanocarrier surface. This intermediary structure enables selective delivery to the target cells while minimizing off-target effects.
Solution Approach 2:
The patent applies local quality by concentrating the therapeutic effect specifically at the Schlemm's canal endothelial cells through targeted delivery. The nanocarrier system ensures that cell softening agents are delivered only to the intended target site (SC endothelial cells in the conventional outflow pathway) rather than diffusely throughout the eye, thereby achieving localized therapeutic action with reduced systemic side effects.
2Reliability
If conventional outflow pathway resistance is not addressed, then current treatments fail to effectively lower intraocular pressure, but existing approaches only reduce aqueous humor inflow or increase unconventional outflow
Solution Approach 1:
The patent extracts and addresses the specific problem of conventional outflow pathway resistance by targeting Schlemm's canal endothelial cells directly. Instead of using general approaches that reduce inflow or increase unconventional outflow, the invention extracts the specific mechanism of action needed (cell softening of SC endothelium) and delivers it selectively to the site of outflow resistance, thereby directly addressing the root cause of elevated intraocular pressure.
3Productivity
If cell softening agents are used to improve aqueous humor outflow, then outflow resistance is reduced, but side effects such as conjunctival hyperemia and cornea verticillata occur
Solution Approach 1:
The nanocarrier system serves as an intermediary delivery vehicle that transports cell softening agents specifically to Schlemm's canal endothelial cells. The targeting moiety comprising FLT4-binding peptide, PEG spacer, and hydrophobic anchor enables selective accumulation at the target site, thereby improving aqueous humor outflow through SC while minimizing exposure of other ocular tissues to the therapeutic agent and reducing associated side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The targeted delivery system significantly reduces intraocular pressure by selectively softening Schlemm's canal endothelial cells, achieving a 30-50% decrease in pressure and prolonged efficacy, while minimizing off-target effects.
Implementation Method 1
a peptide that specifically binds to SC endothelial cells
Implementation Method 2
a nanocarrier comprising a poly(ethylene glycol)-block-poly(propylene sulfide) (PEG-b-PPS) copolymer
Implementation Method 3
a hydrophobic anchor
Implementation Method 4
Cell softening agents, such as actin depolymerizers
Data Source
AI summary
The present invention provides systems for targeted delivery of therapeutic agents to Schlemm's canal (SC) endothelial cells. Also provided are methods for using the systems to treat glaucoma or reduce intraocular pressure.